Analysts' Activity: Mannkind Corporation (MNKD)

Marco Green
November 14, 2017

Based on an average daily volume of 27,541,901 shares, the days-to-cover ratio is now 1.0 days. The expected future growth in earnings per share ("EPS") is an incredibly important factor.in identifying an under-valued stock.

Shares of MannKind (NASDAQ:MNKD) were downgraded to a Hold by stock research analysts at Maxim Group.

Mannkind Corporation (NASDAQ:MNKD)'s revenue estimates for the current quarter are $4.43 Million according to 2 number of analysts, for the current quarter the company has high revenue estimates of $4.66 Million in contradiction of low revenue estimates of $4.2 Million. Finally, ValuEngine lowered shares of MannKind Corporation from a "buy" rating to a "hold" rating in a research note on Tuesday, August 1st.

Investors are often dealing with the decision of whether to sell a stock that has been a solid performer or hold on to it for more profit. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $0.92. It has a market cap of $371.04 Million. The shares were acquired at an average cost of $6.00 per share, with a total value of $999,600.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. They issued a "buy" rating on the stock.

A number of institutional investors and hedge funds have recently modified their holdings of MNKD. LMR Partners LLP purchased a new stake in MannKind Corporation during the 2nd quarter worth approximately $352,000. The company's a year ago sales total was 12400.

Harel Insurance Investments & Financial Services Ltd. downsized its ownership by shedding 2,460,000 shares a decrease of 83.4%. Looking further out we can see that the stock has moved over the year to date.

Currently Mannkind Corporation (NASDAQ:MNKD)'s shares owned by insiders are 0.2%, whereas shares owned by institutional owners are 14.6%. The 14-day RSI is now sitting at 46.22, the 7-day is at 43.54, and the 3-day is spotted at 55.25 for Mannkind Corp (MNKD). The stock remained 1.81% unpredictable for the week and 1.83% for the month.

Mannkind Corporation (NASDAQ:MNKD) shares traded -0.93% down during most recent session to reach at the closing price of $3.21. The share last price represents downtick move of -53.45% in value from company's 52-Week high price and shows 386.34% above change in value from its 52-Week low price.

The P/E ratio is N/A and the market value is 362.99M.

On the other hand Mannkind Corporation (NASDAQ:MNKD) has Relative Strength Index (RSI 14) of 45.42 along with Average True Range (ATR 14) of 0.56.

MannKind Corporation (NASDAQ:MNKD) last announced its earnings results on Tuesday, November 7th. The company's price to sales ratio for trailing twelve months is 0.75 and price to book ratio for most recent quarter is 0.54, whereas price to cash per share for the most recent quarter is 3.61. MannKind Corporation had a negative return on equity of 24.93% and a negative net margin of 155.83%. The company had revenue of $2.04 million for the quarter, compared to analyst estimates of $2.56 million. Total debt to equity ratio of the company for most recent quarter is 0.25 whereas long term debt to equity ratio for most recent quarter is 0.23.

On September 1, 2017 Maxim Group maintained a "Buy" rating on the company.

TRADEMARK VIOLATION WARNING: "Short Interest in MannKind Corporation (MNKD) Increases By 11.3%" was reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this report on another site, it was stolen and republished in violation of United States & global copyright legislation.

MannKind Corporation (MannKind), launched on February 14, 1991, is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Business's product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and also to improve glycemic control.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER